Bansisons Tea Industries Ltd - 519353 - Board Meeting Outcome for Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2026 Along With Auditors Report
Novyra Pharmachem's board approved Q4 and FY26 standalone audited financial results. Q4 FY26 revenue stood at ₹10.44 lakh, reflecting a 117.5% YoY increase, but the company reported a net loss of ₹533.83 lakh, significantly wider than ₹5.02 lakh YoY. For FY26, revenue increased 249% YoY to ₹16.75 lakh, with the net loss expanding to ₹537.38 lakh from ₹6.36 lakh in FY25.
May 02 2026 17:05:00
Bansisons Tea Industries Ltd - 519353 - Board Meeting Intimation for Audited Financial Results Along With The Auditor''s Report And Certificate For Unmodified Opinion Of The Company For The Quarter And Year Ended 31St March, 2026
Novyra Pharmachem Limited announced its Board Meeting, initially scheduled for April 29, 2026, to approve audited Q4 and FY26 financial results, has been postponed. The meeting is now rescheduled for Saturday, May 02, 2026.
Apr 29 2026 19:04:00
Bansisons Tea Industries Ltd - 519353 - Board Meeting Intimation for Audited Financial Results Along With The Auditor''s Report And Certificate For Unmodified Opinion Of The Company For The Quarter And Year Ended 31St March, 2026
Novyra Pharmachem's board meeting to approve Q4 and FY26 audited financial results has been postponed from April 18, 2026, to April 25, 2026. The meeting will consider and approve the financial results along with the Auditor's Report for the period ended March 31, 2026.
Apr 18 2026 17:04:00
Bansisons Tea Industries Ltd - 519353 - Board Meeting Intimation for Audited Financial Result For The Quarter And Financial Year Ended On 31St March, 2026 Along With The Auditor''s Report
Novyra Pharmachem board meeting scheduled for April 18, 2026, to approve audited financial results for the quarter and full financial year ended March 31, 2026. The trading window has been closed since April 1, 2026.
Apr 08 2026 19:04:00
Read More